Vaccine Candidate More than 90% Effective in Preventing the Virus, Says Pfizer
Pfizer, a biopharmaceutical company, and BioNTech, an immunotherapy company, announced on Monday, November 9, 2020, that BNT162b2, the vaccine candidate against COVID-19 which they have jointly developed, has already succeeded in the first interim efficacy analysis from the clinical phase 3 study.
According to Pfizer, their vaccine candidate has demonstrated evidence of efficacy against the virus in participants without evidence of prior infection. The vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants.
“Today is a great day for science and humanity. The first set of results from our Phase 3 COVID-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent COVID-19.”
– Dr. Albert Bourla, Pfizer Chairman and CEO
“We are reaching this critical milestone in our vaccine development program at a time when the world needs it most with infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen,” Bourla added.
“The first interim analysis of our global Phase 3 study provides evidence that a vaccine may effectively prevent COVID-19. This is a victory for innovation, science and a global collaborative effort.”
– Prof. Ugur Sahin, BioNTech co-founder and CEO
The trial for the vaccine candidate BNT162b2 is expected to continue through the final analysis. Both companies are now working to prepare the necessary safety and manufacturing data to submit to the FDA. Up to 50 million vaccine doses are expected to be produced globally in 2020 and up to 1.3 billion doses in 2021 based on the current projections Pfizer.
For More News and Updates
Looking for more news and updates like this one? Feel free to explore our Baguio City Guide website and our official Baguio City Guide Facebook page to catch more content.
Source: Pfizer Inc.
How do you feel about this?
